- phx.corporate-ir.net/External.File?item…t=1Jul 2, 2013 - Inhibits two key steps of cell wall synthesis: – Transglycosylation. – Transpeptidation. • Disrupts bacterial membrane integrity. Differentiated from …
FDA Accepts Filing of NDA for IV Antibiotic Oritavancin with Priority Review
Oritavancin (INN, also known as LY333328) is a novel semi-synthetic glycopeptide antibiotic being developed for the treatment of serious Gram-positive infections. Originally discovered and developed by Eli Lilly, oritavancin was acquired by InterMune in 2001 and then by Targanta Therapeuticsin late 2005.
Results have been presented (in 2003) but possibly not yet published from two pivotal Phase 3 clinical trials testing the efficacy of daily intravenous oritavancin for the treatment of complicated skin and skin-structure infections (cSSSI) caused by Gram-positive bacteria. The primary endpoints of both studies were successfully met, with oritavancin achieving efficacy with fewer days of therapy than the comparator agents (vancomycin followed by cephalexin). In addition, oritavancin showed a significantly improved safety profile with a 19.2 percent relative reduction in the overall incidence of adverse events versus vancomycin/cephalexin (p<0.001) in the second and larger pivotal trial.
About The Medicines Company
- LY 333328 diphosphate
- LY333328 diphosphate
- Oritavancin diphosphate
- 192564-14-0 CAS NO
- Targanta Revives Oritavancin: Next Weapon Against cSSSI? BioWorld Today, November 26, 2007
- “Biotechs pick up slack in antibiotics development”. 17 May 2011.
- http://www.farm.ucl.ac.be/Full-texts-FARM/Domenech-2009-1.pdf ”Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization” 2009
- Scheinfeld, N (2007). “A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus“.J Drugs Dermatol. 6 (4): 97–103. PMID 17373167.
- 2007 ICAAC Posters: E-1612 “In Vitro Activity Profile of Oritavancin against a Broad Spectrum of Aerobic and Anaerobic Bacterial Pathogens”/E -1613 “In Vitro Activity Profile of Oritavancin (ORI) Against Organisms Demonstrating Key Resistance Profiles to Other Antimicrobial Agents”/E-1614 “In vitro Time Kill Studies of Oritavancin against Drug-resistant Isolates ofStaphylococcus aureus and Enterococci”/E-1615 “Anti-Enterococcal Activity Profile of Oritavancin, a Potent Lipoglycopeptide under Development for Use Against Gram-Positive Infections”/E-1616 “Anti-Streptococcal Activity Profile of Oritavancin, a Potent Lipoglycopeptide under Development for Use Against Gram-Positive Infections”/E-1617 “In Vitro Activity Profile of Oritavancin (ORI) Against Resistant Staphylococcal Populations From a Recent Surveillance Initiative”/E-1620 “Pharmacokinetic Concentrations of Oritavancin Kill Stationary-Phase and Biofilm Staphylococcus aureus In Vitro.” / Targanta Press Release September 19, 2007
- ICAAC 2007 Posters: “In Vitro Susceptibility of Genotypically Distinct Clostridium difficileStrains to Oritavancin” and “Activity of Metronidazole, Vancomycin and Oritavancin Against Epidemic Clostridium difficile Spores” / Targanta Press Release September 19, 2007
- ASM 2007 Poster: “Efficacy of Oritavancin in a Murine Model of Bacillus anthracis Spore Inhalation Anthrax” / Targanta Press Release May 24, 2007
- Belley; McKay, GA; Arhin, FF; Sarmiento, I; Beaulieu, S; Fadhil, I; Parr Jr, TR; Moeck, G (2010).“Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-Resistant Enterococci To Effect Rapid Bacterial Killing”. Antimicrobial agents and chemotherapy 54(12): 5369–71. doi:10.1128/AAC.00760-10. PMC 2981232. PMID 20876372.
- Zhanel et al. (2012). “Oritavancin: Mechanism of Action”. Clin Infect Dis.doi:10.1093/cid/cir920.
- ICAAC 2003 Late-breaker poster: “Phase III Trial Comparing 3-7 days of Oritavancin vs. 10-14 days of Vancomycin/Cephalexin in the Treatment of Patients with Complicated Skin and Skin Structure Infections (cSSSI)” / InterMune Press Release September 15, 2003
- ClinicalTrials.gov NCT00514527
- Comparison of the Efficacy and Safety of Oritavancin Front-Loaded Dosing Regimens to Daily Dosing: An Analysis of the SIMPLIFI Trial. May 2011. doi:10.1128/AAC.00029-11.
- “Drugs.com, Targanta Submits Oritavancin New Drug Application”. Retrieved 2008-02-12.
- “FDA News, Targanta to Get FDA Decision by December”. Retrieved 2008-04-10.
- http://www.fiercebiotech.com/press-releases/fda-issues-complete-response-letter-oritavancin Dec 2008.
- “Pharmaceutical Business Review, EMEA accepts Targanta’s oritavancin MAA for review”. Retrieved 2008-06-26.
- Antimicrobial Agents and Chemotherapy, 2003 , vol. 47, 5 p. 1700 – 1706
- Antimicrobial Agents and Chemotherapy, 1999 , vol. 43, 1 p. 115 – 120
- Antimicrobial Agents and Chemotherapy, 1997 , vol. 41, 10 p. 2165 – 2172
- Tetrahedron, 2004 , vol. 60, 47 p. 10611 – 10618………… NMRhttp://www.sciencedirect.com/science/article/pii/S0040402004015108
|EP0435503A1 *||Dec 11, 1990||Jul 3, 1991||Eli Lilly And Company||Improvements in or relating to gylcopeptide derivatives|
|US4639433 *||Aug 14, 1985||Jan 27, 1987||Eli Lilly And Company||Glycopeptide derivatives|
|US4698327 *||Apr 18, 1986||Oct 6, 1987||Eli Lilly And Company||Novel glycopeptide derivatives|
|US20040106590 *||Aug 29, 2003||Jun 3, 2004||Barry Eisenstein||Methods and reagents for treating infections of clostridium difficile and diseases associated therewith|
|US20050197333||Dec 22, 2004||Sep 8, 2005||Van Duzer John H.||Rifamycin analogs and uses thereof|
|US20070014849||Sep 20, 2006||Jan 18, 2007||Daniela Jabes||Use of ramoplanin to treat diseases associated with the use of antibiotics|
|US20030176327 *||Oct 18, 2002||Sep 18, 2003||Cassell Gail Houston||Antibiotics for treating biohazardous bacterial agents|
|US20040147441||Aug 25, 2003||Jul 29, 2004||Leach Timothy S.||Methods and reagents for preventing bacteremias|
|WO1999010006A1||Aug 18, 1998||Mar 4, 1999||Lilly Co Eli||Therapy for staphylococcus aureus|
|WO2000066144A2||Apr 19, 2000||Nov 9, 2000||Lilly Co Eli||Monthly doses of glycopeptide antibiotics for treatment of streptococcus pneumoniae infections|
|WO2008097364A2||Sep 24, 2007||Aug 14, 2008||Targanta Therapeutics Corp||Use of oritavancin for prevention and treatment of anthrax|
|WO1998052592A1 *||May 5, 1998||Nov 26, 1998||Lilly Co Eli||Urea and thiourea derivatives of glycopeptides|
|WO2002036612A1 *||Nov 2, 2001||May 10, 2002||Univ Cambridge Tech||Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane-associating elements|
|WO2007138999A1||May 25, 2007||Dec 6, 2007||Shionogi & Co||Glycopeptide antibiotic derivative|
|WO2009081958A1||Dec 25, 2008||Jul 2, 2009||Shionogi & Co||Glycosylated glycopeptide antibiotic derivative|
|EP2314599A1||Nov 24, 2005||Apr 27, 2011||National University Corporation Nagoya University||Glycopeptide antibiotic monomer derivatives|
|US5919756 *||May 1, 1997||Jul 6, 1999||Eli Lilly And Company||Amides|
|US5919771 *||Apr 30, 1998||Jul 6, 1999||Eli Lilly And Company||Urea and thiourea derivatives of glycopeptides|
|US7078380||Nov 2, 2001||Jul 18, 2006||Cambridge University Technical Services Limited||Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane associating elements|
|US8481696||Dec 25, 2008||Jul 9, 2013||Shionogi & Co., Ltd.||Glycosylated glycopeptide antibiotic derivatives|